Form 4: BioXcel Director Mack Acquires Shares via RSU Vesting

BioXcel Therapeutics Director David J. Mack acquired 1,694 shares of common stock through the vesting of Restricted Stock Units.

Summary

• David J. Mack, a Director of BioXcel Therapeutics, Inc. (BTAI), acquired 1,694 shares of common stock.
• The acquisition occurred on September 30, 2025, as a result of the vesting of Restricted Stock Units (RSUs).
• Following this transaction, David J. Mack beneficially owns 18,623 shares of BioXcel Therapeutics Common Stock.
• The RSUs represent a contingent right to receive one share of the Issuer's Common Stock per unit.
• The Reporting Person was originally granted 20,317 RSUs on November 21, 2024.
• These RSUs vest in twelve equal installments on the last day of each month, beginning November 30, 2024, contingent on continued service as a Director.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director's increased ownership, even through routine vesting, generally signals continued alignment with shareholder interests. However, it's a standard compensation event and not indicative of new strategic moves or significant financial performance.

Positives

• The acquisition of shares by a director, even through vesting, increases their direct ownership and aligns their interests more closely with those of shareholders.

Future Outlook

The remaining Restricted Stock Units granted on November 21, 2024, will continue to vest in equal monthly installments on the last day of each month, subject to David J. Mack's continued service as a Director through the vesting period.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation, which is a common practice across publicly traded companies in all industries, including biotechnology. It does not provide information on broader industry trends or competitive positioning.

Related Party Transactions

• The acquisition of shares by Director David J. Mack through the vesting of Restricted Stock Units is a transaction between a related party (director) and the company, representing a standard component of executive and director compensation.

Stakeholder Impact

• Shareholders: A minor increase in the number of outstanding shares due to RSU conversion, but also increased alignment of a director's interests with shareholders through greater equity ownership.
• Employees: No direct impact mentioned for general employees.
• Customers, Suppliers, Creditors: No direct impact.

Next Steps

• Continued vesting of the remaining Restricted Stock Units in equal monthly installments on the last day of each month, subject to the director's continued service.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, David J. Mack, Director, Restricted Stock Units, RSU vesting, Common Stock, Insider transaction, SEC Form 4